异搏定对膀胱癌耐药性的逆转研究

首都医科大学学报 ›› 2005, Vol. 26 ›› Issue (3): 339-341.

异搏定对膀胱癌耐药性的逆转研究

周永建¹, 周鑫¹, 赵玉千¹, 韩志兴¹, 吴长利²

1. 首都医科大学附属北京天坛医院泌尿外科;2. 天津医科大学泌尿外科研究所

收稿日期:2004-05-24 修回日期:1900-01-01 出版日期:2005-06-24 发布日期:2005-06-24

Verapamil Reversing Effects on Drug Resistance in Bladder Cancer

Zhou Yongjian¹, Zhou Xin¹, Zhao Yuqian¹, Han Zhixing¹, Wu Changli²

1. Department of Urology, Beijing Tiantan Hospital, Capital University of Medical Sciences;2. Institute of Urinary, Tianjin Medical University

Received:2004-05-24 Revised:1900-01-01 Online:2005-06-24 Published:2005-06-24

摘要/Abstract

摘要：

目的通过钙通道阻滞剂异搏定阻止抗癌药物从细胞内排出,探讨肿瘤细胞抗药性逆转的可能性.方法利用氮唑化合物(MTT)试验方法及高效液相色谱分析(HPLC)方法检测应用异搏定后肿瘤细胞对抗癌药物敏感性的改变.结果发现异搏定对膀胱癌敏感细胞(EJ)的生长无影响,而对膀胱癌耐药细胞(EJ-R)则随着异搏定质量浓度的增加,化疗药物的抗癌作用逐渐增强.结论异搏定通过阻滞钙通道,降低P-GP₁₇₀排出抗癌药物的作用,使癌细胞内抗癌药物浓度得到保证,达到杀死肿瘤细胞的目的,即癌细胞抗药性得到逆转。

关键词: 膀胱癌, 抗药性, 多药耐药基因

Abstract:

Objective The hypothesis was under investigation that verapamil as a Calcium-channel antagonist, is introduced to prevent excretion of anticancer drugs from cells excerting reversing effects on drug resistance in bladder cancer. Methods MTT and HPLC method are applied to detect the alteration on the sensibility of cancer cells to anticancer drugs before and after introducing verapamil. Results Verapamil has no effect on the growth of bladder cancer-sensible cells(EJ). For the drug-resisted bladder cancer cells (EJ-R), effects of anti-cancer drugs are enhanced with the increasing concentration of verapamil. Conclusion Glucoprotein P-GP_ 170 on the membranes of bladder cancer cells can excrete anti-cancer drugs from the cells against concentration gradient. Verapamil blocks Calcium channels thereby reduce excretion of anti-cancer drugs by P-GP₁₇₀. By guaranteening the concentration of anti-cancer drugs in the cancer cells, drug resistance of cancer cells is reversed.

Key words: bladder cancer, drug resistance, muti-drug resistance gene

中图分类号:

R737.14

周永建;周鑫;赵玉千;韩志兴;吴长利. 异搏定对膀胱癌耐药性的逆转研究[J]. 首都医科大学学报, 2005, 26(3): 339-341.

Zhou Yongjian;Zhou Xin;Zhao Yuqian;Han Zhixing;Wu Changli. Verapamil Reversing Effects on Drug Resistance in Bladder Cancer[J]. Journal of Capital Medical University, 2005, 26(3): 339-341.

[1]	丁显超, 宋黎明, 瓦斯里江·瓦哈甫, 牛亦农. 二次电切对非肌层浸润性膀胱癌疗效的影响分析[J]. 首都医科大学学报, 2019, 40(1): 84-89.
[2]	瓦斯里江·瓦哈甫, 刘赛, 王梦童, 贺庆豹, 宋黎明, 平浩, 王明帅, 杨飞亚, 田溪泉, 牛亦农, 邢念增. 膀胱癌根治术前单次动脉灌注化疗的长期疗效评估[J]. 首都医科大学学报, 2018, 39(3): 418-422.
[3]	陈思阳, 丰琅, 杜源, 杜林栋. 经尿道针状电极膀胱肿瘤整块切除术与经尿道钬激光膀胱肿瘤切除术治疗非肌层浸润性膀胱癌的治疗效果和安全性比较[J]. 首都医科大学学报, 2018, 39(3): 439-443.
[4]	闫伟, 康雯婷, 陈山, 刘跃新. 荧光原位杂交技术在膀胱尿路上皮癌术后复发的早期检测中的临床应用价值[J]. 首都医科大学学报, 2014, 35(3): 298-301.
[5]	田野. 应重视化疗在肌层浸润性膀胱癌保留膀胱治疗中的作用[J]. 首都医科大学学报, 2014, 35(3): 269-272.
[6]	李光;张海峰;徐妙生;王全红. 膀胱癌等位基因缺失研究[J]. 首都医科大学学报, 2008, 29(1): 81-84.
[7]	刘志远;许淑珍;于艳华. 万古霉素耐药肠球菌基因检测及同源性分析[J]. 首都医科大学学报, 2007, 28(2): 173-175.
[8]	张子顺;赵玉千;吴长利. 膀胱癌组织MDR₁基因产物P-GP₁₇₀表达的意义[J]. 首都医科大学学报, 1999, 20(3): 202-204.
[9]	马素兰;张玉书;赵宏;李文竹;黎启祥;陈永和. 39例表浅膀胱癌经尿道切除术后放疗的临床疗效观察[J]. 首都医科大学学报, 1997, 18(2): 157-159.